Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?
Dublin Academic Medical Centre, Centre for Arthritis and Rheumatic Diseases, St Vincent's University Hospital and The Conway Institute of Biomolecular and Biomedical Research, University College Dublin, , Dublin, Ireland.
Carl
C
Orr
Douglas James
DJ
Veale
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D018664:Interleukin-12 / Q000276:immunology; D020381:Interleukin-17 / Q000276:immunology; D053759:Interleukin-23 / Q000276:immunology; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D008727:Methotrexate / Q000627:therapeutic use; D015398:Signal Transduction / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology; D000069549:Ustekinumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D020381:Interleukin-17; D053759:Interleukin-23; D007555:Isoxazoles; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; C555450:secukinumab; D000069549:Ustekinumab; D000077339:Leflunomide; D008727:Methotrexate
DMARDs (biologic); Psoriatic Arthritis; Treatment